Madison Taliaferro spent weeks in the hospital in 2012. After a decade of suffering from cystic fibrosis, she underwent a double lung transplant. She powered through the difficult surgery and the recovery that followed –long days of physical therapy and rehabilitation. Her parents were there. Her best friend visited from Kansas. Grandparents rotated shifts so she was never alone. But one request still lingered.
“I just wanted to see my dogs,” she remembers.
Having suffered from the effects of chronic illness for the decade prior, Madison was no stranger to long days at home, isolated from the school germs that could turn her illness into a critical condition with a single sneeze. When her friends couldn’t visit, her dogs were there. But at the hospital, they weren’t.
To view the multimedia release go to:
http://www.multivu.com/players/English/7835951-purina-family-pet-center-st-louis-childrens/
Federally funded research continues to spur progress against cancer; however, accelerating the pace of progress will require robust, sustained, and predictable annual funding increases for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA). Additionally, strong financial support for the National Cancer Moonshot Initiative is required, according to the sixth annual American Association for Cancer Research (AACR) Cancer Progress Report, released today.
One of the most exciting new approaches to cancer treatment is cancer immunotherapy. As detailed in the report, the utility of immunotherapy is expanding rapidly. For example, on Aug. 1, 2015, one class of immunotherapeutics, checkpoint inhibitors, was initially approved for just two types of cancer—melanoma and lung cancer. As of Sept. 1, 2016, checkpoint inhibitors have been approved for treating six types of cancer—bladder cancer, head and neck cancer, Hodgkin lymphoma, kidney cancer, lung cancer, and melanoma.
To view the multimedia release go to:
http://www.multivu.com/players/English/7911951-aacr-2016-cancer-progress-report/
Lustgarten Foundation funded researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins have designed a multi-analyte blood test that can detect the presence of pancreatic cancer as part of a panel of eight common cancers (pancreas, ovary, liver, stomach, esophagus, colorectum, lung and breast) as reported in the online edition of Science today. The test utilizes combined assays for genetic alterations and protein biomarkers and has the capacity not only to identify the presence of relatively early cancer, but also to localize the organ of origin of these cancers.
“The potential this has for pancreatic cancer is unprecedented,” says Anne Marie Lennon, M.D., Ph.D., Associate Professor of Medicine, Director, Pancreatic Cyst Center of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center. “We know that in 80-85 percent of pancreatic cancer cases, it’s detected too late, leaving the patient with few options. Developing a blood screening test for pancreatic cancer has been an urgent goal, because catching the disease early will be the way we get to long-term survival.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213751-lustgarten-foundation-pancreatic-cancer-blood-test/
Boehringer Ingelheim announced today a new partnership with Minor League Baseball® (MiLB™) to further raise awareness of the rare lung disease idiopathic pulmonary fibrosis (IPF) through its Breathless™ campaign. Now the “Official IPF Awareness Partner of Minor League Baseball,” Boehringer Ingelheim will work with the league to educate its fan base about symptoms of IPF – and the importance of an early diagnosis and treatment – through in-stadium events as well as appearances by New York Yankees legend and musician Bernie Williams, whose father passed away from the disease in 2001.
To view the multimedia release go to:
https://www.multivu.com/players/English/8289951-boehringer-ingelheim-milb-partnership-for-ipf-awareness/
